Home » Topics » BioWorld Science

BioWorld Science
RSS

Glactone Pharma Development patents STAT3 inhibitors

July 3, 2018

Dafclir receives approval in Japan

July 3, 2018

Topline data reported from phase IIa trial of IRL-752 in Parkinson's disease dementia

July 3, 2018

TRIGR Therapeutics and ABL Bio collaborate in immuno-oncology

July 3, 2018

Advicenne reports preliminary phase III extension study results for ADV-7103

July 3, 2018

Phase I/II data presented for FT-2102, a mutant IDH1 inhibitor, in AML or MDS patients

July 3, 2018

Compugen announces IND clearances for BAY-1905254 and COM-701

July 3, 2018

FDA grants fast track designation to CUTX-101 for treatment of classic Menkes disease

July 3, 2018

FDA awards regenerative medicine advanced therapy designation to romyelocel-L

July 3, 2018

Ocugen initiates first pivotal trial of OCU-300 for ocular graft-versus-host disease

July 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...